USMLE Step 2 CK gynecology & breast questions

Short stature, webbed neck, shield chest, absent breast development, and markedly elevated gonadotropins (hypergonadotropic hypogonadism) in an adolescent girl point to gonadal dysgenesis from Turner syndrome (45,X or mosaicism). Streak ovaries fail to produce estrogen, removing negative feedback and causing high FSH/LH. Karyotype confirms the diagnosis. Associated findings include coarctation of the aorta and bicuspid aortic valve, which should be screened for with echocardiography.

• A. PCOS causes oligomenorrhea with normal or low FSH, not primary amenorrhea with absent breast development.
• B. Kallmann syndrome causes hypogonadotropic (low, not elevated) hypogonadism with anosmia.
• C. Asherman syndrome is intrauterine scarring from instrumentation, not a cause of absent puberty.
• E. Androgen insensitivity syndrome occurs in 46,XY individuals with normal breast development and no uterus.

Normal breast development occurs because peripheral aromatization of testosterone to estrogen is intact, while absence of the uterus reflects normal anti-Müllerian hormone secretion by functioning testes. Sparse pubic and axillary hair reflects end-organ resistance to androgens at the hair follicle due to a defective androgen receptor. A 46,XY karyotype with normal-to-high male testosterone levels confirms androgen insensitivity syndrome rather than a Müllerian anomaly. Gonadectomy is typically deferred until after puberty because of malignancy risk versus the benefit of endogenous estrogen production.

• A. Turner syndrome is 45,X with hypergonadotropic hypogonadism and streak gonads, not a 46,XY karyotype.
• B. Müllerian agenesis occurs in 46,XX females with normal ovarian function and normal pubic/axillary hair.
• C. 5-alpha-reductase deficiency presents with ambiguous or undervirilized male genitalia at birth, not a female phenotype with normal breasts.
• D. Congenital adrenal hyperplasia in a 46,XY individual would not cause absent uterus with normal breast development.

A negative progesterone withdrawal test means the endometrium was not primed by estrogen, pointing to either an estrogen-deficient state (hypothalamic-pituitary-ovarian dysfunction) or an outflow tract/endometrial problem such as Asherman syndrome. The estrogen-progesterone challenge test administers exogenous estrogen to prime the endometrium, then progesterone to induce withdrawal bleeding; if bleeding occurs, the outflow tract is intact and the problem is inadequate estrogen production, while absent bleeding points to a uterine or outflow tract abnormality. This test distinguishes between hypoestrogenic causes and anatomic causes before pursuing further workup. It is a logical, guideline-based next step before invasive testing like hysteroscopy.

• B. Starting hormonal contraception without first confirming the cause of amenorrhea does not establish a diagnosis.
• C. Karyotype is reserved for primary amenorrhea with suspected gonadal dysgenesis, not secondary amenorrhea in a previously menstruating woman.
• D. Reassurance without further workup is inappropriate given 5 months of amenorrhea and an abnormal progesterone challenge.
• E. Androgen levels are indicated when there is hirsutism or virilization, not as the next step after a negative progesterone challenge.

Functional hypothalamic amenorrhea results from energy deficiency, excessive exercise, or psychological stress suppressing hypothalamic GnRH pulsatility. Reduced GnRH pulse frequency and amplitude lead to low FSH and LH, which in turn cause low estradiol production by the ovaries (hypogonadotropic hypogonadism). This is a diagnosis of exclusion after ruling out other causes of hypothalamic-pituitary dysfunction. Management includes correcting energy balance, weight restoration, and reducing exercise intensity to restore normal menstrual function.

• A. Autoimmune oophoritis causes primary ovarian insufficiency with elevated, not low, FSH and LH.
• C. Prolactin was not reported as elevated in this patient, and hyperprolactinemia is a separate diagnosis.
• D. Increased peripheral aromatization would raise estrogen levels, not lower them with associated low gonadotropins.
• E. Endometrial resistance to estrogen is not a recognized mechanism of amenorrhea in this context.

Amenorrhea after uterine instrumentation with normal hormone levels and no withdrawal bleeding on estrogen-progesterone challenge is characteristic of Asherman syndrome, caused by intrauterine adhesions (synechiae) that destroy the functional endometrium. Hysteroscopy is both the most accurate diagnostic test and the therapeutic procedure, allowing direct visualization and lysis of adhesions under direct vision. Transvaginal ultrasound or sonohysterography can suggest adhesions but hysteroscopy remains the gold standard for diagnosis and treatment. Normal gonadotropins and prolactin exclude ovarian failure and hyperprolactinemia as causes.

• A. Diagnostic laparoscopy visualizes the pelvic and abdominal cavity externally, not the uterine cavity itself.
• C. Transvaginal ultrasound may suggest a thin or irregular endometrium but is less sensitive and specific than hysteroscopy for diagnosing intrauterine adhesions.
• D. Endometrial biopsy samples endometrial tissue but cannot visualize or treat intrauterine adhesions.
• E. Anti-Müllerian hormone reflects ovarian reserve, not endometrial or intrauterine cavity pathology.

In any reproductive-age woman presenting with abnormal uterine bleeding, pregnancy must be excluded first, since pregnancy-related causes (ectopic pregnancy, miscarriage, molar pregnancy) require urgent and different management than structural or ovulatory causes. Once pregnancy is ruled out, pelvic ultrasound is typically the next step to evaluate for structural causes such as fibroids, polyps, or endometrial abnormalities. This stepwise approach follows the PALM-COEIN framework for classifying abnormal uterine bleeding. Skipping the pregnancy test risks missing a potentially life-threatening cause of bleeding.

• A. Endometrial biopsy is used to evaluate endometrial pathology, typically after pregnancy exclusion and imaging, especially in women over 45 or with risk factors.
• C. Hysteroscopy is a later diagnostic or therapeutic step, not the initial evaluation.
• D. Ultrasound is an appropriate next step but only after pregnancy has been excluded.
• E. A CBC assesses the degree of anemia from bleeding but does not address the most urgent initial concern of pregnancy status.

Heavy menstrual bleeding beginning at menarche accompanied by mucocutaneous bleeding symptoms such as epistaxis and easy bruising, with a normal platelet count and normal PT/PTT, is classic for von Willebrand disease, the most common inherited bleeding disorder. Von Willebrand factor antigen level and ristocetin cofactor activity assay are the standard initial tests to diagnose this condition, as PT and PTT can be normal even with clinically significant von Willebrand disease. All adolescents with heavy menstrual bleeding since menarche should be screened for bleeding disorders per ACOG guidance. Early diagnosis guides management with desmopressin or von Willebrand factor concentrate during bleeding episodes.

• A. A peripheral smear would be useful to evaluate for platelet or red cell abnormalities but does not diagnose von Willebrand disease.
• C. Bleeding time is an outdated, nonspecific test that has largely been replaced by specific von Willebrand factor assays.
• D. Bone marrow biopsy evaluates marrow production disorders, not an inherited coagulopathy with normal platelet count.
• E. A factor VIII inhibitor assay is used to evaluate acquired hemophilia, not suspected von Willebrand disease.

The Rotterdam criteria require two of three features: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound (≥20 follicles of 2-9 mm in at least one ovary, per 2018 criteria, or the older ≥12-follicle threshold), after exclusion of other causes. This patient has irregular cycles, hirsutism with mildly elevated testosterone, and polycystic-appearing ovaries, satisfying all three criteria. Normal TSH and prolactin exclude thyroid dysfunction and hyperprolactinemia as alternative explanations for the oligomenorrhea.

• B. An androgen-secreting tumor typically causes rapid-onset virilization with markedly elevated testosterone (>150-200 ng/dL), not this gradual, mild elevation.
• C. Nonclassic CAH would be considered if 17-hydroxyprogesterone were elevated, which was not tested or suggested here; PCOS is a diagnosis of exclusion but remains most likely with this presentation.
• D. Hypothalamic amenorrhea presents with low or absent gonadotropins and estrogen, not hyperandrogenism or polycystic ovarian morphology.
• E. Normal TSH excludes hypothyroidism as the cause of her menstrual irregularity.

In PCOS, hyperinsulinemia acts synergistically with LH on ovarian theca cells, amplifying androgen (testosterone and androstenedione) biosynthesis via the insulin-like growth factor-1 receptor pathway. Insulin also suppresses hepatic synthesis of sex hormone-binding globulin (SHBG), which increases the fraction of free, biologically active testosterone. This combination of increased production and decreased binding explains the clinical hyperandrogenism (hirsutism, acne) seen in insulin-resistant PCOS patients. This is why insulin-sensitizing strategies such as weight loss and metformin can improve hyperandrogenic symptoms.

• A. LH hypersecretion in PCOS arises primarily from altered GnRH pulsatility, not a direct pituitary action of insulin.
• B. Increased peripheral aromatization would raise estrogen and lower androgen levels, which is the opposite of the clinical picture in PCOS.
• D. Insulin resistance lowers, not raises, hepatic SHBG production, which increases rather than decreases free testosterone.
• E. Hyperinsulinemia does not suppress cortisol synthesis, and adrenal androgen excess is not the primary mechanism of PCOS-related hyperandrogenism.

Combined oral contraceptives are first-line therapy for women with PCOS who do not desire pregnancy because the progestin component provides regular endometrial shedding, protecting against endometrial hyperplasia from unopposed estrogen exposure due to chronic anovulation. The estrogen component also increases hepatic SHBG production, lowering free testosterone and improving hirsutism and acne over several months. This patient has no contraindications (no migraine with aura, hypertension, smoking, or thrombosis history), making combined OCPs appropriate and effective for her combined goals of contraception, cycle regulation, and hyperandrogenism management.

• B. Danazol is an androgenic steroid used for endometriosis and would exacerbate hirsutism rather than improve it.
• C. Testosterone would worsen her hyperandrogenism and is contraindicated in this setting.
• D. Emergency contraception is used for a single act of unprotected intercourse, not for ongoing cycle regulation or endometrial protection.
• E. GnRH agonists like leuprolide cause hypoestrogenism and are not standard therapy for PCOS-related oligomenorrhea or hirsutism.

Letrozole, an aromatase inhibitor, is recommended as first-line ovulation induction therapy for women with PCOS and anovulatory infertility, based on data showing higher live birth rates compared with clomiphene citrate, particularly in obese women with PCOS. Letrozole works by transiently lowering estrogen levels, which reduces negative feedback on the hypothalamic-pituitary axis and increases FSH secretion, promoting follicular development. Clomiphene remains an acceptable alternative but is no longer considered first-line given letrozole's superior live birth and ovulation rates in major trials.

• A. Bromocriptine treats hyperprolactinemia-associated anovulation, which is not indicated here given no mention of elevated prolactin.
• B. Clomiphene was historically first-line but has been superseded by letrozole, which produces higher live birth rates in PCOS-related infertility.
• D. hCG triggers ovulation after follicular development is induced by letrozole or clomiphene; it is not used alone for induction.
• E. Metformin improves insulin sensitivity but is less effective than letrozole or clomiphene as a sole ovulation induction agent.

A morning (follicular phase) serum 17-hydroxyprogesterone level is the best screening test to distinguish nonclassic congenital adrenal hyperplasia, caused by partial 21-hydroxylase deficiency, from PCOS in a patient with hirsutism and oligomenorrhea. A level below 200 ng/dL makes nonclassic CAH unlikely, while a level above 200 ng/dL (some sources cite >2 ng/mL as screening cutoff) warrants a cosyntropin stimulation test for confirmation. This distinction matters because management and genetic counseling implications differ between the two conditions. An elevated LH:FSH ratio can support PCOS but is neither sensitive nor specific enough to exclude nonclassic CAH.

• A. SHBG levels are often low in both PCOS and hyperandrogenic states and do not differentiate between the two conditions.
• C. Urinary free cortisol screens for Cushing syndrome, which is not the differential being considered here.
• D. An elevated LH:FSH ratio is suggestive but not diagnostic of PCOS and does not reliably exclude nonclassic CAH.
• E. Anti-Müllerian hormone is often elevated in PCOS due to increased antral follicle count but does not distinguish it from nonclassic CAH.

This patient meets three of the four Amsel criteria: thin homogeneous discharge, vaginal pH greater than 4.5, positive whiff test with KOH, and clue cells (epithelial cells with stippled borders due to adherent coccobacilli) on wet mount, which is diagnostic of bacterial vaginosis. Only three of four criteria are required for diagnosis. BV results from a shift from Lactobacillus-dominant flora to anaerobic organisms such as Gardnerella vaginalis. There is typically no vulvovaginal inflammation, which distinguishes BV from candidiasis or trichomoniasis despite the overlapping term "vaginosis" implying absence of inflammation.

• B. Chlamydial cervicitis typically shows mucopurulent cervical discharge and friability, not clue cells on wet mount.
• C. Candidal vulvovaginitis causes pruritic thick white discharge with pseudohyphae on KOH prep and a normal vaginal pH.
• D. Trichomoniasis shows motile flagellated organisms on wet mount and often causes vulvar irritation and a strawberry cervix, not clue cells.
• E. Atrophic vaginitis occurs in postmenopausal women with low estrogen and causes dryness and petechiae, not clue cells or a positive whiff test.

Symptomatic bacterial vaginosis should be treated in both pregnant and nonpregnant patients, and oral metronidazole 500 mg twice daily for 7 days is the preferred regimen in pregnancy. Metronidazole is considered safe throughout pregnancy and is not associated with teratogenicity despite earlier concerns. Treating symptomatic BV in pregnancy relieves symptoms, though it does not reliably reduce the risk of preterm birth in low-risk women. Doxycycline is avoided in pregnancy due to effects on fetal bone and teeth, and fluconazole is used for candidiasis, not BV.

• A. Symptomatic bacterial vaginosis should be treated in pregnancy to relieve symptoms, regardless of preterm birth risk considerations.
• C. Fluconazole treats candidiasis, not bacterial vaginosis, and is also avoided at high doses in pregnancy due to teratogenic risk.
• D. Doxycycline is contraindicated in pregnancy because it causes fetal tooth discoloration and inhibits bone growth.
• E. Oral therapy is preferred over intravaginal therapy in pregnancy, and treatment should not be deferred in a symptomatic patient.

Motile, flagellated, pear-shaped organisms on saline wet mount combined with a strawberry cervix (punctate hemorrhages) and an elevated vaginal pH are classic for Trichomonas vaginalis infection. Diagnosis is confirmed by wet mount or, preferably, nucleic acid amplification testing for higher sensitivity. Treatment is oral metronidazole for the patient, and her sexual partner should also be treated to prevent reinfection, since trichomoniasis is sexually transmitted. Unlike BV or candidiasis, trichomoniasis warrants partner treatment and is reportable in some jurisdictions.

• B. Gonococcal cervicitis is diagnosed by NAAT or culture, not by visualizing flagellated organisms on wet mount.
• C. Candidiasis causes thick white discharge with pseudohyphae on KOH prep, not motile organisms on saline wet mount.
• D. Desquamative inflammatory vaginitis shows parabasal cells and increased white blood cells without motile organisms, typically in a different clinical context.
• E. Bacterial vaginosis shows clue cells, not motile flagellated organisms, and does not cause a strawberry cervix.

The USPSTF recommends annual screening for Chlamydia trachomatis in all sexually active women age 24 years and younger, regardless of symptoms, because infection is frequently asymptomatic and can lead to pelvic inflammatory disease and infertility if untreated. Screening is typically performed with urine or vaginal nucleic acid amplification testing and does not require a pelvic examination. Women 25 and older are screened if they have risk factors such as a new or multiple partners. This patient's age and sexual activity meet the criteria for routine annual screening.

• A. Chlamydia screening is independent of cervical cytology results and should be performed regardless of Pap smear findings.
• B. One-time screening is insufficient; annual screening continues through age 24 for sexually active women.
• C. Chlamydia infection is often asymptomatic, which is precisely why routine screening is recommended rather than symptom-based testing.
• D. Screening is recommended annually for all sexually active women 24 years and younger, not only after a recent new partner.

Mucopurulent cervical discharge and friability in a sexually active patient with a new partner are consistent with cervicitis, most commonly due to Chlamydia trachomatis or Neisseria gonorrhoeae. Current CDC guidelines recommend empiric treatment while NAAT results are pending with ceftriaxone (500 mg IM for patients under 150 kg) plus doxycycline 100 mg orally twice daily for 7 days, covering both gonorrhea and chlamydia simultaneously. Azithromycin alone is no longer first-line for chlamydia due to doxycycline's superior efficacy and concerns about resistance patterns. Treating empirically prevents complications such as PID and reduces transmission while awaiting confirmatory testing.

• B. Ciprofloxacin is not recommended for gonorrhea due to widespread fluoroquinolone resistance in Neisseria gonorrhoeae.
• C. Metronidazole treats bacterial vaginosis and trichomoniasis, not gonococcal or chlamydial cervicitis.
• D. Azithromycin alone no longer reliably covers both gonorrhea and chlamydia and is not the preferred first-line regimen for chlamydia.
• E. Fluconazole treats candidiasis and has no activity against gonorrhea or chlamydia.

In a sexually active woman with pelvic or lower abdominal pain, the presence of cervical motion tenderness, uterine tenderness, or adnexal tenderness is a minimal clinical criterion sufficient to begin empiric treatment for pelvic inflammatory disease, since no single test is sensitive or specific enough to confirm the diagnosis and delayed treatment increases risk of infertility and ectopic pregnancy. CDC guidelines recommend a low threshold for empiric treatment in at-risk women once other causes such as pregnancy have been excluded. Additional findings such as fever, elevated inflammatory markers, or mucopurulent discharge support but are not required for the diagnosis. Imaging or laparoscopy may be used selectively but should not delay empiric therapy.

• B. Laparoscopy is reserved for diagnostic uncertainty or suspected complications, not for routine confirmation before treatment.
• C. Ultrasound is not required before starting empiric treatment and should not delay therapy in a patient meeting minimal criteria.
• D. Withholding treatment risks progression to tubo-ovarian abscess and long-term sequelae such as infertility.
• E. Treatment should not be delayed for NAAT results given the low threshold for empiric therapy based on clinical criteria.

Tubo-ovarian abscess (TOA) is a severe sequela of pelvic inflammatory disease in which inflammation and subsequent fibrosis distort and obstruct the fallopian tubes. Scarring of the tubal mucosa and peritubal adhesions impair ovum transport, leading to tubal factor infertility and a markedly increased risk of ectopic pregnancy if conception does occur. The severity and chronicity of inflammation, not ovarian or endometrial damage, is the dominant mechanism of infertility after TOA. Prevention relies on early recognition and treatment of PID before abscess formation.

• A. Luteal phase defect is not a recognized consequence of resolved tubo-ovarian abscess.
• C. PID and TOA do not typically cause hypothalamic-pituitary dysfunction or anovulation.
• D. TOA damages the tube and surrounding peritoneum, not primarily ovarian follicular reserve.
• E. Asherman syndrome follows intrauterine instrumentation (e.g., curettage), not adnexal infection.

Current USPSTF and ACOG guidelines recommend initiating cervical cancer screening at age 21 years regardless of sexual history, using cytology (Pap test) alone every 3 years for women aged 21-29 years. HPV testing is not recommended in this age group because of the high prevalence of transient HPV infections that would lead to unnecessary colposcopies. Co-testing with cytology and HPV, or primary HPV testing, becomes an option starting at age 30 years. Screening should not be deferred based on sexual activity patterns since it is age-based.

• B. Primary HPV testing is not recommended for women younger than 30 years due to high rates of transient infection.
• C. Screening should begin at age 21 years, not be delayed to 30, regardless of risk factors.
• D. Screening intervals are determined by age, not triggered solely by changes in sexual partners.
• E. Co-testing is an option starting at age 30 years, not for women in their twenties.

When a Pap smear shows ASC-US and HPV co-testing is positive for high-risk HPV, the patient should proceed directly to colposcopy for further evaluation, since the combination indicates a higher risk of underlying cervical intraepithelial neoplasia than ASC-US with negative HPV testing. If HPV testing had been negative, the patient could safely return to routine screening in 3 years. Colposcopy allows direct visualization and biopsy of abnormal-appearing cervical epithelium to determine whether CIN is present and its grade. Risk-based management guides the decision rather than cytology result alone.

• A. Endometrial biopsy evaluates the endometrium for abnormal bleeding, not cervical cytologic abnormalities.
• C. LEEP is a treatment for confirmed CIN 2/3, not the initial step after an abnormal screening result.
• D. Returning to a 3-year interval is reserved for ASC-US with negative HPV co-testing.
• E. Repeat testing in 1 year is appropriate only for certain lower-risk scenarios, not ASC-US with positive high-risk HPV.

A cytology result of HSIL mandates colposcopy with directed biopsy regardless of HPV status, because HSIL carries a substantial risk of underlying CIN 2/3 or invasive cancer that requires histologic confirmation before definitive treatment. Colposcopy allows visualization of the transformation zone and targeted biopsy of acetowhite or abnormal vascular areas to establish a tissue diagnosis. An excisional procedure without prior biopsy is not appropriate because it would treat before confirming the diagnosis and extent of disease. Delaying evaluation with repeat cytology is inappropriate given the high-risk nature of an HSIL result.

• A. Performing excision before histologic confirmation risks overtreatment and misses the opportunity to assess margins based on biopsy-confirmed disease extent.
• B. Reassurance is inappropriate given the significant risk of CIN 2/3 or cancer associated with HSIL cytology.
• D. HPV genotyping does not change management since HSIL cytology already mandates colposcopy irrespective of HPV status.
• E. Repeat cytology in 6 months is insufficient surveillance for a high-grade result and risks delayed diagnosis of invasive disease.

Loop electrosurgical excision procedure (LEEP) is the preferred treatment for CIN 2/3 in reproductive-age women who wish to preserve fertility, as it removes the transformation zone for both diagnostic margin assessment and therapeutic excision while sparing the uterus. LEEP has high success rates in eradicating high-grade dysplasia and allows histologic evaluation of margins to confirm complete excision. Hysterectomy is reserved for women who do not desire fertility, have recurrent disease, or have other gynecologic indications. Cryotherapy is an older, less precise ablative method generally not preferred when excisional diagnosis is needed.

• A. Observation is not appropriate for CIN 3, which carries a significant risk of progression to invasive cancer if untreated.
• C. Cryotherapy is an ablative technique that does not provide a tissue specimen for margin assessment and is less preferred than excision for CIN 2/3.
• D. Simple hysterectomy eliminates future fertility and is not first-line for CIN 2/3 in a woman desiring childbearing.
• E. Radical trachelectomy is a fertility-sparing option for early invasive cervical cancer, not for preinvasive CIN 2/3.

The Advisory Committee on Immunization Practices (ACIP) recommends routine HPV vaccination starting at age 11-12 years, though the series can begin as early as age 9 years, with catch-up vaccination recommended for all individuals through age 26 years who were not adequately vaccinated earlier. Vaccination at younger ages is associated with a more robust immune response, and completing the series before sexual debut maximizes preventive benefit against HPV-related cancers, including cervical cancer. Shared clinical decision-making for vaccination between ages 27 and 45 years is also an option based on individual risk, though it is not routinely recommended. The vaccine is recommended for both males and females.

• B. Vaccination can begin as early as age 9, but routine vaccination is targeted at 11-12 years, and catch-up through age 26 is recommended.
• C. HPV vaccination is recommended for both males and females given the virus's role in multiple cancers in both sexes.
• D. HPV vaccine is not part of the newborn immunization schedule and is not administered at birth.
• E. Routine vaccination is recommended at 11-12 years, well before this later age range, to maximize immune response and effectiveness prior to exposure.

Postcoital bleeding combined with a friable, ulcerated, exophytic cervical mass in a woman who has not had cervical cancer screening is the classic presentation of invasive cervical cancer, most commonly squamous cell carcinoma. The friable surface bleeds easily on contact (including during intercourse or speculum exam) because of abnormal, fragile tumor vasculature. Diagnosis requires histologic confirmation by biopsy of the visible lesion. Lack of recent screening is a major risk factor since most cervical cancers arise from undetected progression of untreated cervical intraepithelial neoplasia.

• B. Leiomyomas are smooth, firm, non-friable masses that do not typically ulcerate or bleed on contact.
• C. Ectropion is a smooth, red, glandular area around the os that may bleed slightly but does not form an ulcerated exophytic mass.
• D. Endocervical polyps are small, smooth, pedunculated lesions, not large ulcerated masses.
• E. Endometrial cancer typically presents with abnormal uterine bleeding in a postmenopausal woman and an enlarged uterus or thickened endometrium, not a visible friable cervical mass.

High-risk HPV types (such as 16 and 18) encode the E6 and E7 oncoproteins, which are central to carcinogenesis. E6 promotes degradation of p53, impairing apoptosis and DNA damage response, while E7 binds and inactivates the retinoblastoma protein (pRb), releasing E2F to drive uncontrolled cell cycle progression. Persistent infection (rather than transient infection, which is usually cleared by the immune system) allows sustained expression of these oncoproteins, leading to accumulation of genetic damage and progression from dysplasia to invasive carcinoma. This mechanism underlies the strong association between persistent high-risk HPV infection and cervical intraepithelial neoplasia/cancer.

• A. HPV does not encode a DNA polymerase that causes mismatch repair mutations; it relies on host replication machinery.
• B. Capsid proteins (L1/L2) are structural and involved in viral assembly and immunity, not oncogenic transformation.
• C. HPV does not act primarily through RAS point mutations; its oncogenic effect is mediated by E6/E7 disrupting tumor suppressors.
• D. Telomerase activation can occur late in carcinogenesis but is not the primary mechanism by which HPV initiates transformation.

Heavy menstrual bleeding, bulk symptoms (pelvic pressure, urinary frequency), and an irregularly enlarged firm uterus are classic for uterine leiomyomas (fibroids). Ultrasound findings of well-circumscribed hypoechoic masses with whorled internal architecture are characteristic sonographic features of leiomyomas, which arise from smooth muscle of the myometrium. Fibroids are the most common pelvic tumor in women of reproductive age and frequently cause anemia from chronic heavy bleeding, as seen in this patient's hemoglobin level.

• A. Adenomyosis causes a diffusely enlarged, globular, tender uterus with poorly defined junctional zone changes, not discrete well-circumscribed whorled masses.
• B. Endometrial carcinoma typically presents with abnormal bleeding and endometrial thickening in older women, not discrete whorled myometrial masses.
• D. Endometrial polyps are usually small, focal, and arise from the endometrium; they would not cause marked uterine enlargement to 16-week size.
• E. Ovarian fibromas are solid adnexal masses separate from the uterus, not myometrial masses causing uterine enlargement.

Asymptomatic fibroids that are not distorting the endometrial cavity and are not causing bleeding, pain, or bulk symptoms do not require treatment, regardless of fertility plans, since most intramural fibroids without cavity distortion do not impair fertility. The appropriate management is expectant management with routine clinical follow-up to monitor for development of symptoms or growth. Intervention is reserved for fibroids that cause symptoms (heavy bleeding, bulk symptoms) or that distort the endometrial cavity and are suspected to contribute to infertility or pregnancy loss.

• A. Endometrial ablation is a treatment for abnormal uterine bleeding and is contraindicated in women desiring future fertility.
• B. GnRH agonists are used for preoperative shrinkage of symptomatic fibroids or short-term symptom control, not indicated for an asymptomatic fibroid.
• D. Myomectomy is invasive and reserved for symptomatic fibroids or those causing cavity distortion affecting fertility, not indicated in an asymptomatic patient.
• E. Uterine artery embolization is a treatment for symptomatic fibroids and is generally avoided in women desiring future fertility due to risk of ovarian insufficiency and placental complications.

Adenomyosis is characterized by ectopic endometrial glands and stroma within the myometrium, producing a diffusely enlarged, globular, tender uterus and symptoms of dysmenorrhea and heavy menstrual bleeding. While transvaginal ultrasound is the first-line imaging test, pelvic MRI is the most accurate noninvasive test when ultrasound findings are equivocal, because it can clearly demonstrate a thickened, poorly defined junctional zone (typically greater than 12 mm) between the endometrium and myometrium, which is the hallmark finding of adenomyosis.

• A. Laparoscopy visualizes the uterine serosal surface and pelvic organs but cannot directly diagnose adenomyosis, which is a myometrial process confirmed by imaging or histology.
• C. Hysterosalpingography evaluates tubal patency and uterine cavity contour, not myometrial infiltration, and is not used to diagnose adenomyosis.
• D. CA-125 may be mildly elevated in adenomyosis but is nonspecific and not diagnostic.
• E. Endometrial biopsy samples only the endometrial lining and cannot detect ectopic glands within the myometrium.

In a postmenopausal woman with bleeding, an endometrial thickness greater than 4 mm on transvaginal ultrasound requires tissue sampling to exclude endometrial hyperplasia or carcinoma, since thickness above this threshold is associated with a clinically significant risk of malignancy. Endometrial biopsy is the appropriate and minimally invasive best test to obtain this tissue diagnosis. If biopsy is nondiagnostic or insufficient tissue is obtained despite a persistently thickened endometrium, hysteroscopy with directed biopsy or dilation and curettage should follow.

• A. Reassurance without tissue diagnosis risks missing endometrial hyperplasia or carcinoma in a patient with postmenopausal bleeding and a thickened endometrium.
• B. Hysterectomy is premature without a tissue diagnosis confirming malignancy or another indication.
• D. Hormonal therapy is not appropriate before excluding malignancy and could mask or stimulate abnormal endometrial tissue.
• E. Delaying evaluation with repeat imaging is inappropriate when the endometrium is already thickened above the biopsy threshold in a symptomatic patient.

Atypical endometrial hyperplasia carries up to a 25-30% risk of concurrent or progression to endometrial carcinoma, so hysterectomy is the recommended definitive treatment in women who do not desire fertility preservation. Progestin therapy (oral or levonorgestrel IUD) is reserved for women who wish to preserve fertility or who are poor surgical candidates, with close surveillance. Dilation and curettage is diagnostic, not therapeutic, and repeat biopsy alone would delay definitive treatment of a lesion with substantial malignant potential.

• A. Curettage only samples tissue; it does not treat the underlying atypical hyperplasia.
• B. The levonorgestrel IUD is a fertility-sparing alternative, not the preferred approach when childbearing is complete.
• D. Progestin therapy is an option only for fertility preservation or when surgery is contraindicated, not first-line here.
• E. Delaying definitive treatment with surveillance alone risks missing a concurrent carcinoma.

In PCOS and obesity, chronic anovulation and peripheral aromatization of androgens in adipose tissue produce continuous estrogen exposure without the cyclic progesterone secretion that normally occurs after ovulation. This unopposed estrogen drives sustained endometrial proliferation, which can progress through hyperplasia to carcinoma. The same mechanism underlies increased risk with estrogen-only hormone therapy, early menarche, late menopause, and nulliparity, since progesterone normally counteracts estrogen-driven proliferation. Tamoxifen also increases risk through its partial estrogen agonist effect on the endometrium despite being an estrogen antagonist in breast tissue.

• B. Anovulation results in a lack of progesterone, not progesterone dominance, which removes the protective opposition to estrogen.
• C. Excess androgens are aromatized to estrogen peripherally, but the carcinogenic effect is through estrogen receptor-mediated proliferation, not direct androgen-induced mutation.
• D. The primary mechanism is proliferative stimulation by estrogen, not an isolated effect on receptor expression.
• E. Insulin resistance contributes indirectly via obesity-related estrogen production but does not cause endometrial atrophy, the opposite occurs.

Diagnostic laparoscopy with direct visualization and histologic confirmation of ectopic endometrial glands and stroma remains the gold standard for definitive diagnosis of endometriosis, particularly when imaging is normal but clinical suspicion remains high. It also allows simultaneous surgical treatment of visible implants and adhesions. CA-125 is neither sensitive nor specific and is more useful for monitoring than diagnosis. MRI can suggest endometriomas or deep infiltrating disease but cannot provide tissue confirmation.

• A. MRI can identify deep infiltrating lesions or endometriomas but does not provide histologic confirmation.
• C. CA-125 may be elevated in endometriosis but lacks sensitivity and specificity for diagnosis.
• D. Symptomatic improvement with empiric therapy suggests but does not confirm the diagnosis.
• E. Hysterosalpingography evaluates tubal patency and uterine cavity contour, not peritoneal implants.

Standard infertility evaluation begins with the least invasive, highest-yield tests: semen analysis for the male partner and confirmation of ovulation (regular cycles with molimina suggest ovulation, but this should be objectively confirmed, e.g., with a midluteal progesterone level or ovulation predictor kits) for the female partner. Male factor and ovulatory dysfunction together account for a large proportion of infertility cases and are quick, inexpensive, and noninvasive to assess. More invasive tests such as hysterosalpingography or laparoscopy are reserved for after these initial results are known or when there are specific risk factors for tubal or anatomic disease.

• A. Tubal evaluation is appropriate after confirming semen parameters and ovulatory status, or sooner if risk factors for tubal disease exist.
• B. Laparoscopy is invasive and reserved for suspected pelvic pathology (e.g., endometriosis) after initial noninvasive workup.
• D. Empiric ovulation induction should not be started before completing a basic infertility evaluation of both partners.
• E. AMH assesses ovarian reserve and is not the first step in a couple with regular cycles and no risk factors for diminished reserve.

Hysterosalpingography (HSG) is the standard initial test to assess tubal patency and uterine cavity contour in the infertility workup, particularly in a patient with a history of pelvic infection such as chlamydia, which increases the risk of tubal scarring and occlusion. Contrast is injected through the cervix under fluoroscopy, and spillage into the peritoneal cavity confirms tubal patency. It is less invasive and less costly than laparoscopy, which is reserved for cases with an abnormal HSG or suspected endometriosis/adhesions requiring direct visualization and treatment.

• A. Endometrial biopsy is not part of the standard infertility workup for tubal factor and does not assess tubal patency.
• B. Laparoscopy with chromopertubation is more invasive and typically reserved for cases with an abnormal HSG or additional findings suggesting pelvic pathology.
• C. AMH assesses ovarian reserve, not tubal patency, and would not explain a history-related risk for tubal factor infertility.
• E. Transvaginal ultrasound evaluates ovarian and uterine anatomy but cannot reliably assess tubal patency.

Shortening of the menstrual cycle in a woman in her late 30s is a classic early sign of diminished ovarian reserve. Early follicular phase (day 2-4) FSH and anti-Müllerian hormone (AMH) are the most useful tests: FSH rises as negative feedback from inhibin B and estradiol declines, and AMH, produced by small antral follicles, falls proportionally with the shrinking follicle pool. AMH is particularly useful because it can be measured at any point in the cycle and correlates well with antral follicle count. These results guide counseling about likelihood of conception and urgency of fertility treatment.

• A. A random LH level is not a standard or reliable marker of ovarian reserve.
• C. Midluteal progesterone confirms ovulation, not ovarian reserve.
• D. Estradiol alone, especially at day 21, does not reliably reflect ovarian reserve and is not the standard test.
• E. TSH screens for thyroid dysfunction as a cause of infertility but does not assess ovarian reserve.

Premature ovarian insufficiency (POI) is diagnosed in women younger than 40 years with amenorrhea for at least 4 months and two serum FSH levels in the menopausal range (typically greater than 25-40 mIU/mL) measured at least one month apart, accompanied by low estradiol and hypoestrogenic symptoms such as hot flashes and vaginal dryness. It results from accelerated follicular depletion or dysfunction. Further workup includes karyotype, FMR1 premutation testing (fragile X), and adrenal antibody testing to evaluate for underlying causes, and patients require hormone therapy to prevent bone loss and cardiovascular risk until the age of natural menopause.

• A. Hypothalamic amenorrhea is characterized by low or normal FSH and low estradiol, not elevated FSH.
• B. Asherman syndrome causes amenorrhea due to intrauterine adhesions, with normal FSH and estradiol levels.
• C. PCOS causes anovulation with normal or low FSH and typically normal or elevated estrogen, not hypoestrogenic symptoms.
• D. A prolactinoma would present with elevated prolactin, which was normal in this patient.

Cabergoline, a dopamine D2-receptor agonist, is the first-line treatment for hyperprolactinemia caused by a prolactin-secreting pituitary microadenoma. Dopamine normally inhibits prolactin secretion from lactotroph cells; dopamine agonists restore this inhibitory tone, lowering prolactin levels, shrinking the tumor, and restoring ovulatory menstrual cycles and fertility in most patients. Cabergoline is preferred over bromocriptine because of its greater efficacy, longer half-life allowing less frequent dosing, and better tolerability. Surgery is reserved for dopamine agonist-resistant tumors or those causing mass effect despite medical therapy.

• A. Letrozole is an alternative ovulation induction agent but also does not treat the prolactinoma itself.
• B. Clomiphene is an ovulation induction agent used once prolactin is normalized; it does not address the underlying hyperprolactinemia.
• D. Transsphenoidal surgery is reserved for cases resistant to or intolerant of dopamine agonist therapy, not as initial treatment.
• E. Leuprolide is a GnRH agonist used for conditions like endometriosis or fibroids, not for hyperprolactinemia.

This patient has stage II anterior vaginal wall (cystocele) pelvic organ prolapse, defined by descent of the leading edge to within 1 cm of the hymenal plane on examination with Valsalva (POP-Q staging). For symptomatic prolapse in a patient who wishes to avoid surgery and remain sexually active, a vaginal pessary is an appropriate first-line, nonsurgical option that can be self-managed or fitted in the office and does not preclude continued intercourse if a suitable type is chosen. Surgical repair is reserved for patients who prefer definitive treatment, fail pessary management, or have more advanced prolapse.

• A. Pelvic floor physical therapy alone has limited efficacy for stage II prolapse with bulge symptoms and does not replace mechanical support from a pessary.
• B. Vaginal estrogen can improve tissue quality and symptoms of atrophy but does not adequately address the mechanical support defect of prolapse.
• D. Surgical colporrhaphy is appropriate for patients opting for surgery, not for a patient who wishes to avoid it initially.
• E. Sacrocolpopexy is a surgical option typically reserved for apical prolapse and for patients who desire or require surgical management, not as an initial step.

Solifenacin is an antimuscarinic agent that selectively blocks M3 muscarinic receptors on the detrusor smooth muscle, reducing involuntary detrusor contractions and improving urgency, frequency, and urge incontinence. Antimuscarinics are first-line pharmacotherapy for overactive bladder after behavioral therapy fails. Mirabegron works through a different mechanism, beta-3 adrenergic agonism, which relaxes the detrusor during filling. The other options are not standard antimuscarinic therapy for overactive bladder.

• A. Mirabegron is a beta-3 adrenergic agonist, not a muscarinic antagonist.
• B. Tamsulosin is an alpha-1 blocker used for benign prostatic hyperplasia, not overactive bladder in women.
• C. Duloxetine is used off-label for stress incontinence by increasing urethral sphincter tone via serotonin-norepinephrine reuptake inhibition.
• E. Desmopressin reduces nocturnal urine production via vasopressin receptor agonism and is used for nocturnal polyuria, not detrusor overactivity.

A personal history of unprovoked venous thromboembolism is an absolute contraindication to systemic estrogen therapy because oral estrogen increases hepatic synthesis of clotting factors and significantly raises the risk of recurrent VTE. Other absolute contraindications include current or past breast cancer, active liver disease, and unexplained vaginal bleeding. This patient should be offered nonhormonal options such as SSRIs/SNRIs or gabapentin for vasomotor symptoms instead. Age alone, well-controlled blood pressure, and the symptoms themselves are not contraindications.

• A. A normal blood pressure supports rather than argues against hormone therapy eligibility.
• C. Age alone is not a contraindication; menopausal hormone therapy is often considered up to age 60 or within 10 years of menopause onset.
• D. Having completed anticoagulation does not eliminate the risk of estrogen-associated VTE recurrence.
• E. Vasomotor symptoms are the indication for therapy, not a contraindication.

Combined hormonal contraceptives are contraindicated in women over age 35 who smoke because the combination markedly increases the risk of myocardial infarction and stroke through estrogen-related prothrombotic and vasoconstrictive effects compounded by smoking-related vascular injury. Other absolute contraindications to combined hormonal contraceptives include migraine with aura at any age, history of venous thromboembolism, and uncontrolled hypertension. This patient should instead be offered a progestin-only method, which does not carry the same cardiovascular risk. The remaining options describe the absence of risk factors, which supports rather than argues against combined hormonal contraceptive use.

• B. Normal blood pressure is reassuring and does not contraindicate combined hormonal contraceptives.
• C. Lack of migraine with aura is reassuring and does not contraindicate combined hormonal contraceptives.
• D. Absence of a VTE history is reassuring and does not contraindicate combined hormonal contraceptives.
• E. Family history of medication use is not a clinical risk factor for contraceptive choice.

Long-acting reversible contraceptives, including the levonorgestrel intrauterine device and the subdermal etonogestrel implant, have the lowest failure rates among reversible methods, with typical-use effectiveness exceeding 99%, because they eliminate dependence on patient adherence. They are appropriate for nulliparous women and provide effective contraception for 3 to 8 years depending on the device, matching this patient's desire for extended pregnancy delay without daily action. Oral pills, the ring, and injections have higher typical-use failure rates due to adherence issues, and condoms have the highest failure rate among listed options.

• A. The vaginal ring requires monthly replacement and has a higher typical-use failure rate than an IUD.
• C. Oral contraceptive pills have higher typical-use failure rates due to need for daily adherence.
• D. The injection requires repeat administration every 3 months and has a higher typical-use failure rate than an IUD.
• E. Condoms have the highest typical-use failure rate among the listed reversible methods.

The copper intrauterine device is the most effective emergency contraceptive, preventing more than 99% of pregnancies when inserted within 5 days of unprotected intercourse, and its efficacy is not reduced by elevated BMI, unlike oral levonorgestrel. It also provides the added benefit of ongoing highly effective contraception for up to 10 years, though this patient's preference against ongoing hormonal methods is satisfied since copper IUDs are nonhormonal. Oral levonorgestrel loses efficacy in women with BMI over 30 kg/m² and is less effective after 72 hours. Ulipristal acetate remains effective up to 120 hours and is less affected by BMI than levonorgestrel but is still less effective overall than the copper IUD.

• B. Levonorgestrel has reduced efficacy in women with BMI over 30 kg/m² and this patient is also outside the ideal 72-hour window for maximal effect.
• C. Ulipristal is effective at this time point but is a hormonal method and less effective than the copper IUD overall.
• D. A progestin implant is not indicated for emergency contraception and does not prevent an already-fertilized ovum from implanting.
• E. The Yuzpe method is less effective and causes more nausea than other options; it is rarely used when better alternatives are available.

The USPSTF (2024 update) recommends biennial screening mammography for average-risk women starting at age 40 and continuing through age 74. This update lowered the prior starting age of 50 to 40 in response to rising incidence of breast cancer in women in their 40s. Annual screening has not been shown to confer additional mortality benefit over biennial screening and increases the risk of false positives and overdiagnosis. Clinical breast examination alone is not an adequate substitute for mammography in average-risk screening.

• A. Age 50 is too late; screening should begin at 40 for average-risk women.
• C. Annual screening is not the USPSTF-recommended interval; biennial screening is preferred to balance benefit and harms.
• D. Clinical breast examination alone does not replace mammographic screening starting at age 40.
• E. Age 50 is outdated; current guidelines lower the starting age to 40, and annual intervals are not recommended.

Women with pathogenic BRCA1 or BRCA2 mutations have a markedly elevated lifetime breast cancer risk (up to 70%) and should undergo annual screening with both breast MRI and mammography beginning around age 25-30, since MRI has higher sensitivity for detecting cancer in young, dense breasts. Risk-reducing bilateral mastectomy substantially lowers breast cancer risk and should be discussed and offered as an option, along with risk-reducing salpingo-oophorectomy once childbearing is complete. Average-risk screening protocols starting at age 40 are inadequate for this high-risk population.

• A. Delaying surveillance until age 50 is unsafe given her significantly elevated risk starting in young adulthood.
• B. Ultrasound alone lacks the sensitivity of MRI for high-risk surveillance and should not be the sole modality.
• D. Biennial mammography without MRI underestimates her risk and is inadequate for a BRCA carrier.
• E. Mammography alone starting at 40 is insufficient; BRCA carriers need earlier, dual-modality screening.

Fibroadenomas are the most common benign breast tumor in women under 30 and present as a solitary, firm, rubbery, well-circumscribed, mobile ('slippery') mass that does not fluctuate with the menstrual cycle. Fibrocystic changes, in contrast, present as cyclical, often bilateral tenderness and diffuse nodularity that worsens premenstrually due to hormonal fluctuation and resolves after menses. Ultrasound of a fibroadenoma typically shows a well-defined, homogeneous, hypoechoic solid mass, distinguishing it from the anechoic simple cysts seen in fibrocystic disease. The lack of cyclical variation and the discrete, mobile nature of the mass favor fibroadenoma over fibrocystic change.

• A. Intraductal papilloma classically presents with nipple discharge, not a palpable discrete mobile mass.
• B. Phyllodes tumors are typically larger, rapidly growing masses in older women and are far less common than fibroadenoma in this age group.
• C. A simple cyst would appear anechoic and fluid-filled on ultrasound, not firm and rubbery on exam.
• E. Invasive carcinoma would typically be fixed, irregular, and more common in an older patient, not a mobile smooth mass in a teenager.

In women younger than 30 years with a palpable breast mass, ultrasound is the preferred initial imaging modality because dense glandular breast tissue in younger women reduces mammographic sensitivity and ultrasound avoids radiation exposure. Ultrasound can effectively characterize the mass as solid versus cystic and guide further management, such as biopsy if the mass has suspicious features. Mammography is generally reserved as the initial study in women age 30 and older or as an adjunct if ultrasound findings are indeterminate. MRI and PET are not first-line for the initial evaluation of a palpable mass.

• A. PET scanning is used for staging known malignancy, not initial evaluation of a palpable breast mass.
• C. Ductography is used specifically to evaluate nipple discharge, not a palpable mass.
• D. Mammography has lower sensitivity in dense, glandular breast tissue typical of young women and is not the preferred initial test under age 30.
• E. MRI is reserved for high-risk screening or problem-solving, not as first-line evaluation of a palpable mass.

A BI-RADS 5 mammographic finding, with a spiculated mass and pleomorphic microcalcifications, is highly suggestive of malignancy and warrants image-guided core needle biopsy rather than short-interval follow-up imaging. Core needle biopsy provides a tissue diagnosis with histologic architecture, allowing determination of hormone receptor and HER2 status if cancer is confirmed, which guides treatment planning. Short-interval follow-up is reserved for low-suspicion (BI-RADS 3) findings, not for lesions with high probability of malignancy. Excisional biopsy is unnecessary as an initial step when core needle biopsy can establish the diagnosis less invasively.

• A. Delaying with 6-month follow-up is inappropriate for a BI-RADS 5 lesion with high suspicion of malignancy.
• B. MRI may be used for further characterization or surgical planning but does not provide the tissue diagnosis needed here.
• C. Excisional biopsy under general anesthesia is more invasive than necessary when core needle biopsy can establish the diagnosis.
• D. Fine-needle aspiration provides only cytology, not architectural detail needed for receptor status and histologic subtype.

Lactational mastitis is typically caused by Staphylococcus aureus introduced through cracked nipples, and the diagnosis is made clinically based on fever, localized breast erythema, warmth, and tenderness without a fluctuant mass suggesting abscess. First-line treatment is an oral antistaphylococcal penicillin such as dicloxacillin, and continued breastfeeding (or regular milk expression) on the affected side is encouraged because it promotes drainage and does not harm the infant. Stopping breastfeeding can worsen milk stasis and increase the risk of abscess formation. Mild supportive measures such as warm compresses are adjunctive but antibiotics are required to treat the underlying infection.

• A. Ultrasound is reserved for suspected abscess with a palpable fluctuant mass; it is not required before starting antibiotics in uncomplicated mastitis.
• B. Intravenous vancomycin and stopping breastfeeding entirely are excessive for uncomplicated mastitis without evidence of abscess or severe sepsis.
• C. Antibiotics are necessary because untreated bacterial mastitis can progress to abscess.
• E. There is no need to stop breastfeeding on the affected side; continued nursing promotes drainage and recovery.